Movement Alert|PHARMARON Rises 3.28% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Strength

Market Focus
Aug 18

On August 18, PHARMARON rose 3.28% in regular trading, trading at 31.6 HKD/share, with turnover of 55.32 million HKD.

On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its first-half interim results. The company previously pre-announced H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New signed orders grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%, indicating strong earnings visibility.

Meanwhile, the CXO sector continued its collective rally. Within the Life Sciences Tools and Services sector, GenScript Bio rose 6.9%, WuXi Bio gained 3.81%, and WuXi XDC advanced 3.62%, reflecting sustained industry recovery momentum driving sector-wide valuation repair.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10